Peter Mugyenyi

Last updated

Peter Mugyenyi
Born1949 (age 74–75)
Uganda
NationalityUgandan
CitizenshipUganda
Alma mater Makerere University
(Bachelor of Medicine and Bachelor of Surgery)
Undisclosed Institution
(Diploma in Child Health)
Royal College of Physicians of Ireland
(Fellow of the Royal College of Physicians of Ireland)
Royal College of Physicians of Edinburgh
(Fellow of the Royal College of Physicians of Edinburgh)
Mbarara University
(Honorary Doctor of Science)
Occupation(s)Physician, HIV/AIDS Researcher, Medical Administrator & Author
Years active1972–present
Known for HIV/AIDS Research
Title Medical director, Joint Clinical Research Centre

Peter Ndimbirwe Mugyenyi is a Ugandan physician, HIV/AIDS researcher, medical administrator and author. He is executive director and co-founder of the Joint Clinical Research Centre, and a leading authority on treatment of HIV/AIDS in Africa. [1]

Contents

Early life and education

Mugyenyi was born in Rukungiri District in the Western Region of Uganda, circa 1949. He attended Kings College Budo, a mixed, boarding secondary school, before he was admitted to Makerere University to study human medicine. He graduated with the degree of Bachelor of Medicine and Bachelor of Surgery. Following his studies at Makerere, he had to flee the country in the early 1970s, under the pursuit of Idi Amin’s secret police. He migrated to the United Kingdom, where he obtained the Diploma in Child Health, the title of Fellow of the Royal College of Physicians of Ireland and that of Fellow of the Royal College of Physicians of Edinburgh. In 2003, he was awarded the degree of Doctor of Science, by Mbarara University in Uganda. [2]

Career in the United Kingdom

While in the United Kingdom, he became a successful consultant pediatrician. But in the early 1990s, he voluntarily returned to his native Uganda to help his country battle the AIDS epidemic, which was still expanding at that time. The working conditions were dire and the salary, a mere fraction of his income in the UK. He had to undergo fresh training in HIV epidemiology. [3]

Leadership in the battle for treatment of HIV/AIDS in Africa

He was one of the first prominent figures in the global medical community to argue that Africans could, and would, successfully follow antiretroviral treatment regimens. At that time few people believed that would happen. History has proven him correct. In 1992, Mugyenyi co-founded and became the Medical Director of the Joint Clinical Research Centre, Africa's largest AIDS treatment and research center. He is recognized as one of the leading HIV/AIDS researchers in the world. [3]

In 2002, he ordered a shipment of low-cost generic ARVs from India, in direct defiance of Uganda's patent laws, challenging the authorities to arrest him and refusing to leave the airport until the drugs were allowed into the country and guarantees were given that future shipments would also be cleared.[ citation needed ]

This action led virtually overnight to a tenfold increase in the number of people on ARVs in Uganda, and effectively ended the blockade of low-cost generic AIDS drugs into Africa. Today almost all Africans on ARVs take generics, the great majority of which still come from India. Mugyenyi also played a major consultative role in the formulation of the PEPFAR (‘President's Emergency Plan for AIDS Relief’) program, which was announced at the 2003 State of the Union address by President George W. Bush. Mugyenyi was seated beside Laura Bush when the announcement was made, and President Bush made reference to him in the speech. PEPFAR has since put millions of Africans on lifesaving antiretroviral treatment, and is widely viewed as by far the single most positive legacy of George W. Bush's two terms in the White House. [3]

In September 2003, Mugyenyi was honored by the International Association of Physicians in AIDS Care and presented with the Hero in Medicine Award. [4] In February 2014, he was appointed as an independent Director, to the Board of Cipla, the Indian pharmaceutical company with an ARV manufacturing factory in Uganda. [5] He served as the Chancellor of Mbarara University of Science and Technology, [6] one of Uganda's eight public universities from 22 August 2008 to 28 October 2017. [2] [7]

Authorship

Mugyenyi's landmark 2008 book Genocide by Denial: How Profiteering from HIV/AIDS Killed Millions [8] details how Western governments and drug companies callously oversaw the deaths of millions of Africans who would never have been able to afford their branded drugs. A follow-up to the earlier book, A Cure Too Far: The Struggle to End HIV/AIDS, was published in early 2013. [9]

Mugyenyi's role in the battle for mass antiretroviral treatment in Africa is portrayed in the 2013 film Fire in the Blood, [10] [ better source needed ] and he was invited by the producers to be the guest of honor when the film debuted at the 2013 Sundance Film Festival in Park City, Utah, USA. His appearance generated several standing ovations at Sundance. [3]

See also

Related Research Articles

<span class="mw-page-title-main">President's Emergency Plan for AIDS Relief</span> United States governmental initiative

The United States President's Emergency Plan For AIDS Relief (PEPFAR) is a United States governmental initiative to address the global HIV/AIDS epidemic and help save the lives of those suffering from the disease. Launched by U.S. President George W. Bush in 2003, as of May 2020, PEPFAR has provided about $90 billion in cumulative funding for HIV/AIDS treatment, prevention, and research since its inception, making it the largest global health program focused on a single disease in history until the COVID-19 pandemic. PEPFAR is implemented by a combination of U.S. government agencies in over 50 countries and overseen by the Global AIDS Coordinator at the United States Department of State. As of 2023, PEPFAR has saved over 25 million lives, primarily in sub-Saharan Africa.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

<span class="mw-page-title-main">Makerere University</span> Public university in Kampala, Uganda

Makerere University is Uganda's largest and oldest institution of higher learning, first established as a technical school in 1922, and the oldest currently active university in East Africa. It became an independent national university in 1970. Today, Makerere University is composed of nine colleges and one school, offering programmes for about 36,000 undergraduates and 4,000 postgraduates. These colleges include College of Natural Sciences (CONAS), College of Health Sciences (CHS), College of Engineering Art & Design (CEDAT), College of Agriculture and Environmental Studies (CAES), College Of Business and Management Sciences (CoBAMS), College of Humanities & Social Sciences (CHUSS), College of Computing and Information Sciences (COCIS), College of Veterinary Medicine, Animal Resources & Bio-security (COVAB), College of Education and External Studies (CEES) and Makerere University Business School (MUBS). In addition, Makerere has onother campus in Eastern Uganda Jinja City.

DREAM is an AIDS therapy program promoted by the Christian Community of Sant'Egidio. The Community of Sant'Egidio, based in Rome, was formerly involved in the peace talks in Mozambique, facilitating the eleven rounds of negotiations in Rome that helped to end the Mozambican Civil War. The Community has worked closely with both the Mozambican Ministry of Health and the United States' PEPFAR in order to implement the DREAM program. The DREAM program is designed to give access to free ARV treatment with generic HAART drugs to the poor in Africa on a large scale: So far, 5,000 people are receiving ARV treatment, especially in Mozambique, but the program is being built up also in other countries, including Angola, Cameroon, Democratic Republic of Congo, Eswatini, Guinea, Kenya, Malawi, Nigeria and Tanzania. Despite being free, the program aims at excellence in treatment, providing the best existent range of drugs (HAART) and regular blood testing according to European standards. It is linked with a nutrition program as well as guidance and sanitary education by volunteers, which encourages new patients to comply and come to the appointments. The compliance rate is very high. The annual cost per person and year of the program is $800.

<span class="mw-page-title-main">Gideon Byamugisha</span>

Reverend Canon Gideon Byamugisha is an Anglican priest in Uganda with a parish outside of Kampala. In 1992, he became the first religious leader in Africa to publicly announce that he was HIV positive. In 2009, Byamugisha received the 26th annual Niwano Peace Prize "in recognition of his work to uphold the dignity and human rights of people living with HIV/AIDS".

<span class="mw-page-title-main">Eric Goosby</span> American public health official

Eric Goosby is an American public health official, currently serving as Professor of Medicine and Director of the Center for Global Health Delivery, Diplomacy and Economics, Institute for Global Health Sciences at University of California, San Francisco. Dr. Goosby previously served as the UN Special Envoy on Tuberculosis as well as previously served as the United States Global AIDS Coordinator from 2009 until mid-November 2013. In the role, Goosby directed the U.S. strategy for addressing HIV around the world and led President Obama's implementation of the President's Emergency Plan for AIDS Relief (PEPFAR). Goosby was sworn in during June 2009 and resigned in November 2013, taking a position as a professor at UCSF, where he directs the Center for Global Health Delivery and Diplomacy, a collaboration between UCSF and the University of California, Berkeley.

Quality Chemical Industries Limited (Qcil), formerly Cipla Quality Chemical Industries Limited (CiplaQCIL) is a pharmaceutical manufacturing company, established in Uganda by Ugandans in 2005. The company is committed to advancing wellness and is the largest producer of World Health Organization (WHO) pre-qualified HIV/AIDS and Malaria treatments in the region. According to a 2007 published report, Qcil was the only company in Africa to manufacture triple-combination antiretroviral (ARV) drugs. Qcil currently produces TLD, the latest first-line treatment used to treat and prevent HIV/AIDS. Qcil also manufactures antimalarials (ACTs), including Lumartem, containing artemisinin and lumefantrine, and the Hepatitis B generic medicines Texavir and Zentair.

Charles Mark Lwanga Olweny is a Ugandan physician, oncologist, academic and medical researcher. Currently he is a professor of medicine and Immediate past vice-chancellor at Uganda Martyrs University, based at Nkozi, Mpigi District, in Central Uganda.

The cost of HIV treatment is a complicated issue with an extremely wide range of costs due to varying factors such as the type of antiretroviral therapy and the country in which the treatment is administered. The first line therapy of HIV, or the initial antiretroviral drug regimen for an HIV-infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest cost of antiretroviral therapy, while middle- and high-income tend to have considerably higher costs. Certain prices of HIV drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater HIV drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of HIV drugs.

Francis Xavier Kitaka was a Ugandan biochemist, veterinarian, entrepreneur and industrialist. He is the former chairman of Cipla Quality Chemical Industries Limited (CIPLAQCIL), located in Luzira, a suburb of Kampala, Uganda's capital and largest city. CIPLAQCIL is the only company in Sub-Saharan Africa, that is authorized to manufacture triple therapy antiretroviral drugs.

George W. Baguma, is a Ugandan businessman and entrepreneur. He is the current chief commercial officer and marketing director at Cipla Quality Chemical Industries Limited. George Baguma is a founder investor in QCIL and is a member of the company's board of directors.

Celestino Obua is a Ugandan physician, pharmacologist, academic and academic administrator. He is the current Vice Chancellor of Mbarara University of Science and Technology. He assumed that position on Friday, 24 October 2014. Prior to that, he served as the Deputy Principal of Makerere University College of Health Sciences.

Raphael Owor is a Ugandan physician, pathologist, academic and medical researcher. He is the immediate past Chancellor of Mbarara University of Science and Technology, serving in that capacity from 2003 until 2007. Prior to that, he served as the Dean of Makerere University School of Medicine, after serving as Pathology Professor and Head of Department at Makerere University.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

The Joint Clinical Research Centre (JCRC) is a medical research institution in Uganda, specializing in HIV/AIDS treatment and management.

Cissy Kityo Mutuluuza, is a Ugandan physician, epidemiologist and medical researcher. She is the Executive Director of the Joint Clinical Research Centre, a government-owned medical research institution in Uganda, specializing in HIV/AIDS treatment and management.

Roy D. Mugerwa was a Ugandan physician, cardiologist and researcher. His contribution to the world of academics include being a Professor Emeritus at Makerere University College of Health Sciences in Kampala, cardiology in Uganda, researching HIV/AIDS and tuberculosis, and his efforts to find an effective HIV vaccine.

Professor Paul Waako, is a Ugandan pharmacologist, academic and academic administrator, who serves as the Vice Chancellor of Busitema University, a public university in the Eastern Region of Uganda, since 1 May 2019.

<span class="mw-page-title-main">Diane Havlir</span> US leader of HIV/AIDS work

Diane Havlir is an American physician who is a Professor of Medicine and Chief of the HIV/AIDS Division at the University of California, San Francisco. Her research considers novel therapeutic strategies to improve the lives of people with HIV and to support public health initiatives in East Africa. She was elected to the National Academy of Medicine in 2019.

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.

References

  1. ↑ "2006 World Health Day: Peter Mugyenyi, Uganda". World Health Organization (WHO). 2006. Archived from the original on 28 December 2013. Retrieved 10 March 2015.
  2. 1 2 "The University: Chancellor, Professor Peter Ndimbirwe Mugyenyi". Mbarara University of Science and Technology. 2014. Retrieved 11 March 2015.
  3. 1 2 3 4 "Fire In The Blood: Contributors". Fireintheblood.com. 20 January 2013. Archived from the original on 17 October 2018. Retrieved 10 March 2015.
  4. ↑ "Dr. Peter Mugyenyi Receives The Coveted Hero In Medicine Award". Management Sciences for Health. 17 March 2008. Retrieved 10 March 2015.
  5. ↑ "Cipla Appoints Dr. Peter Mugyenyi As An Independent Director On The Board" (PDF). Cipla.com. 12 February 2014. Retrieved 11 March 2015.
  6. ↑ Tumushabe, Alfred (22 August 2008). "Uganda: Mbarara University Gets New Chancellor". Daily Monitor (Kampala) via AllAfrica.com . Retrieved 11 March 2015.
  7. ↑ "Prof Olweny is new Mbarara University Chancellor". The Independent Uganda. 29 October 2017. Retrieved 27 September 2023.
  8. ↑ Mugyenyi, Peter (30 October 2008). Genocide by Denial: How Profiteering from HIV/AIDS Killed Millions. Fountain Publishers. ISBN   978-9970027538.
  9. ↑ Timbiti, Watuwa (24 February 2013). "Kadaga Commends Ugandan Doctor On HIV". New Vision (Kampala). Retrieved 10 March 2015.
  10. ↑ "Peter Mugyenyi". IMDb .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.